Evogene Partners with Google Cloud to Revolutionize AI in Small Molecule Discovery and Optimization

Evogene's Breakthrough in AI-Driven Molecule Discovery

In a significant advancement for the pharmaceutical and agricultural sectors, Evogene Ltd. (NASDAQ: EVGN) has reported a major milestone in its ongoing partnership with Google Cloud. This collaboration focuses on harnessing artificial intelligence (AI) technology, particularly through the ChemPass AI™ platform, to facilitate autonomous small-molecule discovery and optimization.

The recently achieved milestone centers on the integration of agentic computational systems into Evogene’s cutting-edge ChemPass AI™. This innovative step allows for the swift identification of vital clinical and biological success criteria early in the drug development process. By accelerating discovery timelines, enhancing scalability, and boosting the probability of success, Evogene aims to transform how small molecules are identified and developed.

The Importance of Early Success Criteria

Developing successful small molecules necessitates understanding a spectrum of biological, chemical, clinical, and commercial requirements. These criteria are outlined in a document known as the Target Product Profile (TPP), which is essential for guiding development programs. Traditionally, many candidates meet these complex requirements only at later development stages, often leading to unforeseen challenges that can stall progress.

To mitigate this issue, Evogene’s upgraded ChemPass AI™ employs Google’s advanced Gemini models and the Gemini Enterprise Agent Platform. This technology enhances the depth and timing of biological TPP profiling, ultimately identifying critical criteria that molecules must meet to advance through the development pipeline. By integrating various data types—structural, biological, chemical, and clinical—AI agents can autonomously analyze potential candidates throughout the design and generation processes.

Reducing Development Risks

Evogene's approach aims to address key challenges often encountered during drug development. Specifically, the enhanced ChemPass AI™ seeks to identify viable compounds earlier in the discovery phase, allowing research teams to prioritize opportunities with the highest potential for commercial success before extensive resources are allocated.

The integration underscores the important role of cloud-based AI technologies in fostering innovation within the life sciences. According to Boaz Maoz, Managing Director of Google Cloud Israel, Evogene is well-positioned to redefine molecular discovery using Google Cloud’s AI infrastructure.

“We are thrilled to see Evogene leveraging our full AI stack,” Maoz commented. “This integration not only showcases Evogene's innovative potential but also exemplifies the transformative capabilities of AI within complex biological and chemical research.”

Looking Ahead

Ofer Haviv, the President and CEO of Evogene, emphasized that this milestone brings them closer to their vision of redefining molecular discovery through AI. As the company advances toward more autonomous computational systems, they envisage a future where complex proteins that challenge current therapeutic developments can be tackled more effectively.

By leveraging AI, Evogene is stepping into a transformative era where the discovery and optimization of new molecules can be performed with unparalleled efficiency and accuracy.

As this collaboration progresses, it will be exciting to observe how the integration of AI into drug discovery can redefine the approach to challenges within the pharmaceutical and agricultural industries.

About Evogene Ltd.

Evogene Ltd. (NASDAQ EVGN) (TASE EVGN) specializes in computational biology and chemistry. Pioneering in the generative design of small molecules for drug and agricultural products, Evogene combines technology with industry needs to foster innovation. To learn more, visit Evogene's website.